Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis Jakavi meets primary endpoint in study of acute graft-versus-host disease

      Novartis Jakavi meets primary endpoint in study of acute graft-versus-host disease

      Medical Dialogues Bureau20 Oct 2019 9:35 AM IST
      New Delhi: Novartis recently announced positive topline results from the Phase III REACH2 study evaluating Jakavi (ruxolitinib) in patients with...
      Boehringer Ingelheim enrolls patients in Phase 2 trial of cystic fibrosis treatment

      Boehringer Ingelheim enrolls patients in Phase 2 trial of cystic fibrosis treatment

      Medical Dialogues Bureau20 Oct 2019 9:30 AM IST
      New Delhi: Boehringer Ingelheim recently announced the first patient enrolled in its Phase II clinical trial BALANCE-CF to evaluate a new potential...
      Five drug firms, distributors offer to settle US opioid suits with USD 50 billion package: Report

      Five drug firms, distributors offer to settle US opioid suits with USD 50 billion package: Report

      Medical Dialogues Bureau20 Oct 2019 9:00 AM IST
      Distributors McKesson Corp, Amerisource Bergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson...
      USFDA alerts iconic Johnsons Baby Powder contaminated with Asbestos

      USFDA alerts iconic Johnsons Baby Powder contaminated with Asbestos

      Medical Dialogues Bureau19 Oct 2019 12:34 PM IST
      The move marks the first time the company has recalled its iconic baby powder for possible asbestos contamination, and the first time U.S. regulators...
      Lupin largest, most advanced oral solid dosage facility gets EIR from USFDA

      Lupin largest, most advanced oral solid dosage facility gets EIR from USFDA

      Medical Dialogues Bureau19 Oct 2019 11:16 AM IST
      The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is Lupin Ltd’s largest and most...
      Indoco Remedies successfully clears USFDA inspection of CRO facility AnaCipher

      Indoco Remedies successfully clears USFDA inspection of CRO facility AnaCipher

      Medical Dialogues Bureau19 Oct 2019 11:05 AM IST
      Commenting on this development, Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited said, “This achievement is for the fifth time in a...
      Merck gets European nod for Ebola vaccine Ervebo

      Merck gets European nod for Ebola vaccine Ervebo

      Medical Dialogues Bureau19 Oct 2019 9:15 AM IST
      The European Medicines Agency (EMA) said its human medicines committee (CHMP) has recommended granting conditional marketing authorization in the...
      Eli Lilly pancreatic cancer drug Pegilodecakin fails to meet endpoint

      Eli Lilly pancreatic cancer drug Pegilodecakin fails to meet endpoint

      Medical Dialogues Bureau19 Oct 2019 9:00 AM IST
      New Delhi: Eli Lilly and Company recently announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic...
      Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

      Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

      Medical Dialogues Bureau18 Oct 2019 1:50 PM IST
      Mumbai: Cipla Limited announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited ("VRL") for the...
      Glenmark Receives USFDA ANDA Approval for Abiraterone Acetate Tablets USP, 250 mg

      Glenmark Receives USFDA ANDA Approval for Abiraterone Acetate Tablets USP, 250 mg

      Medical Dialogues Bureau18 Oct 2019 1:40 PM IST
      MUMBAI -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA)...
      USFDA red flag to Torrent Pharmas Indrad facility

      USFDA red flag to Torrent Pharma's Indrad facility

      Medical Dialogues Bureau18 Oct 2019 1:15 PM IST
      New Delhi: The US health regulator has red-flagged Torrent Pharmaceuticals for significant violations of current good manufacturing practice (CGMP)...
      Roche bags FDA approval of Xofluza (baloxavir marboxil) for treatment of acute, uncomplicated influenza

      Roche bags FDA approval of Xofluza (baloxavir marboxil) for treatment of acute, uncomplicated influenza

      Medical Dialogues Bureau18 Oct 2019 12:28 PM IST
      US: Roche today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XofluzaTM...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok